Human Gene Set: GSE7568_IL4_TGFB_DEXAMETHASONE_VS_IL4_TGFB_TREATED_MACROPHAGE_DN


Standard name GSE7568_IL4_TGFB_DEXAMETHASONE_VS_IL4_TGFB_TREATED_MACROPHAGE_DN
Systematic name M371
Brief description Genes down-regulated in macrophages: 5 days with IL4 [GeneID=3565] and dexamethasone [PubChem=5743] followed by TGFB1 [GeneID=7040] for 24h versus 5 days with IL4 [GeneID=3565] followed by TGFB1 [GeneID=7040] for 24h.
Full description or abstract The goal of the study was to identify the effects of TGF-beta on primary human macrophages maturated under different conditions.
Collection C7: Immunologic Signature
      IMMUNESIGDB: ImmuneSigDB
Source publication Pubmed 18453574   Authors: Gratchev A,Kzhyshkowska J,Kannookadan S,Ochsenreiter M,Popova A,Yu X,Mamidi S,Stonehouse-Usselmann E,Muller-Molinet I,Gooi L,Goerdt S
Exact source GSE7568_2507_200_DN
Related gene sets (show 9 additional gene sets from the source publication)

(show 8 gene sets from the same authors)
External links
Filtered by similarity ?
Source species Homo sapiens
Contributed by Jernej Godec (Dana-Farber Cancer Institute)
Source platform or
identifier namespace		 HUMAN_GENE_SYMBOL
Dataset references (show 1 datasets)
Download gene set format: grp | gmt | xml | json | TSV metadata
Compute overlaps ? (show collections to investigate for overlap with this gene set)
Compendia expression profiles ? NG-CHM interactive heatmaps
(Please note that clustering takes a few seconds)
GTEx compendium
Human tissue compendium (Novartis)
Global Cancer Map (Broad Institute)
NCI-60 cell lines (National Cancer Institute)

Legacy heatmaps (PNG)
GTEx compendium
Human tissue compendium (Novartis)
Global Cancer Map (Broad Institute)
NCI-60 cell lines (National Cancer Institute)
Advanced query Further investigate these 175 genes
Gene families ? Categorize these 175 genes by gene family
Show members (show 200 source identifiers mapped to 175 genes)
Version history 7.3: Moved to ImmuneSigDB sub-collection.

See MSigDB license terms here. Please note that certain gene sets have special access terms.